J. Forster

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

M. Berger, S. Stein, C. Geyer, 2006, The New England journal of medicine.

Evidence-Based Liver Chemistry Monitoring in Drug Development

C. Hunt, H. Stirnadel, Julie I. Papay, 2009, Pharmaceutical Medicine.

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.

J. Forster, L. Schwartzberg, P. Wissel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study

P. Ruff, J. Forster, L. Goedhals, 1994 .

Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study

J. Forster, L. Goedhals, X. Froger, 1995 .

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

M. Arbushites, S. Stein, K. Blackwell, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

S. Franco, S. Stein, K. Blackwell, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.